We are live on ! Find out more
PAI

ProQuest Associates IV Portfolio holdings

AUM $53M
1-Year Est. Return 3.35%
This Fund
S&P 500
This Quarter Est. Return
+24.41%
1 Year Est. Return
+3.35%
3 Year Est. Return
+113.14%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$78.2M
AUM Growth
-$254M
Cap. Flow
+$38.4M
Cap. Flow %
49.12%
Top 10 Hldgs %
100%
Holding
5
New
2
Increased
–
Reduced
–
Closed
–

Top Buys

1
URGN icon
UroGen Pharma
URGN
+$25.2M
2
MRSN
Mersana Therapeutics
MRSN
+$13.2M

Top Sells

No sells this quarter

Sector Composition

1 Healthcare 51.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
URGN icon
1
UroGen Pharma
URGN
$1.91B
$26.2M 33.51%
+1,451,329
New +$25.2M
IMDZ
2
DELISTED
Immune Design Corp.
IMDZ
$19.1M 24.47%
1,962,720
– –
AGRX
3
DELISTED
Agile Therapeutics
AGRX
$19M 24.27%
2,531
– –
MRSN
4
DELISTED
Mersana Therapeutics
MRSN
$13.4M 17.07%
+38,228
New +$13.2M
EGRX
5
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$535K 0.68%
3,652,284
– –

Similar funds

CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
HC
Hampstead Capital London, United Kingdom $55.8M AUM 2.76% 1-Year Est. Return
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
SCM
Sorin Capital Management Stamford, Connecticut $56.7M AUM 2.84% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
MCAI
Meritech Capital Associates III Palo Alto, California $45.8M AUM 24.9% 1-Year Est. Return
P
PhaseCapital New York $45.2M AUM 8.85% 1-Year Est. Return